2 results
Approved WMOPending
To establish the safety, tolerability, and early efficacy of multiple doses of hLF1-11 given once daily for 14 days.
Approved WMOPending
Main objectives:• To evaluate whole body distribution of 89Zr-Df-crefmirlimab in cancer patients prior to and during treatment with an anti-PD-1 antibody.• To evaluate pharmacokinetics (PK) of 89Zr-Df-crefmirlimab in patients prior to and during…